Markus Rüegg is a biochemist by training and now Professor of Neurobiology at the Biozentrum of the University of Basel. His main research interests are the molecular pathways involved in muscle wasting diseases in general. He was a founding member of MyoContract Ltd, which later became Santhera Pharmaceuticals Ltd, and was a partner of TREAT-NMD. Markus is a member of scientific panels of Muscular Dystrophy UK and Cure CMD and he is chairman of the scientific council of the Swiss Foundation for Research on Muscle Diseases (FSRMM).